Pembrolizumab May Be Beneficial in a Subset of Soft-Tissue Sarcomas [Research Watch]

Anti–PD-1 therapy with pembrolizumab achieved responses in 18% of patients with soft-tissue sarcoma.

from Cancer via ola Kala on Inoreader http://ift.tt/2xEA01Z
via IFTTT